Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522325 | 0.94 | GBA1 (0.41) | GBA1TSHRUSP2ALDH1A1ALOX15 | |
| SCHEMBL10304159 | 0.89 | SMN1; SMN2 (0.32) | SMN1; SMN2GBA1 | |
| SCHEMBL11328512 | 0.88 | — | — | |
| SCHEMBL6560470 | 0.83 | GBA1 (0.39) | GBA1ALDH1A1TDP1 | |
| SCHEMBL11324571 | 0.82 | GBA1 (0.42) | GBA1ALDH1A1TDP1 | |
| SCHEMBL16254144 | 0.81 | — | — | |
| SCHEMBL17472537 | 0.79 | — | — | |
| SCHEMBL10169614 | 0.76 | CYP1A2 (0.31) | — | |
| SCHEMBL17616826 | 0.75 | — | — | |
| SCHEMBL17900056 | 0.74 | SMN1; SMN2 (0.31) | SMN1; SMN2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-4156097-A | Preparation of 2-cyclopentenyl ethers | UNION CARBIDE CORPORATION (US) | 1979-05-22 | — | — | US | disclosed |
| US-4134924-A | CONTACTING 2-CYCLOPENTENYL CARBOXYLATE OR ALCOHOL WITH LOW PH AQUEOUS ACID SOLUTION | UNION CARBIDE CORPORATION (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | SMN1; SMN2 5/4885GBA1 1485/4885TSHR 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.